Jun. 23 at 12:24 PM
$IMMP Immutep announces initial efficacy data from Phase I study of IMP761
Immutep announces initial efficacy data and continued safety data from the placebo-controlled, double-blind first-in-human Phase I study evaluating IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases. Through the highest dosing level to date, there have been no treatment-related adverse events in healthy participants. Additionally, pharmacodynamic data at this dosing level show that the inhibition of T cell infiltration in the skin at day 10 following a neoantigen rechallenge has already reached 80%. Given the encouraging efficacy and safety, Immutep is continuing with single ascending dose levels of 2.5, 7 and 14 mg/kg.
The LAG-3 immune checkpoint has been identified as a promising therapeutic target for rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis in multiple publications.1-3 IMP761 is the first LAG-3 agonist antibody developed to potentially treat these large and growing disorders, each of which represent multi-billion dollar markets, and many other autoimmune diseases.
By enhancing the "brake" function of LAG-3 to silence dysregulated self-antigen-specific memory T cells, IMP761 is designed to target the cause of autoimmune diseases and restore balance to the immune system. The Phase I trial is being conducted by the Centre for Human Drug Research in Leiden, the Netherlands. In addition to the safety analysis, CHDR is implementing its keyhole limpet haemocyanin challenge model to evaluate IMP761's pharmacological activity. Additional data from the Phase I to follow in second half of CY2025.
